Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down – Here’s Why

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) gapped down before the market opened on Monday . The stock had previously closed at $26.50, but opened at $25.03. Dianthus Therapeutics shares last traded at $30.40, with a volume of 3,618,067 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. William Blair began coverage on Dianthus Therapeutics in a report on Wednesday, July 2nd. They set an “outperform” rating for the company. Wedbush raised their price target on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the company an “outperform” rating in a research report on Thursday, August 21st. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Monday. Finally, Robert W. Baird dropped their target price on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 13th. Seven research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $54.00.

Dianthus Therapeutics Stock Up 19.1%

The business has a fifty day simple moving average of $21.27 and a 200 day simple moving average of $20.03. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -9.82 and a beta of 1.46.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The business had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.87 million. Equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of DNTH. Vestal Point Capital LP raised its position in shares of Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after buying an additional 1,499,931 shares in the last quarter. RA Capital Management L.P. boosted its stake in Dianthus Therapeutics by 53.6% in the first quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company’s stock valued at $52,003,000 after acquiring an additional 1,000,333 shares in the last quarter. Octagon Capital Advisors LP grew its position in Dianthus Therapeutics by 11.0% during the first quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company’s stock valued at $42,478,000 after buying an additional 231,500 shares during the period. Alliancebernstein L.P. raised its stake in Dianthus Therapeutics by 14.5% during the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock worth $21,887,000 after purchasing an additional 149,200 shares during the period. Finally, Janus Henderson Group PLC increased its stake in Dianthus Therapeutics by 14.4% during the 4th quarter. Janus Henderson Group PLC now owns 1,085,648 shares of the company’s stock worth $23,607,000 after buying an additional 136,314 shares during the period. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.